In summary, our genetically modified bifidobacterium displaying
antigen system shows promise as a novel vaccine platform to
induce efficient mucosal immunity. To further develop this novel
oral vaccine platform, we should consider modifying the live vaccine,
such as by freeze-drying, encapsulation, or some other means,
to create more practical needle/syringe-free and cold-chain-free
forms of the mucosal vaccine.